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Abstract
Background: Many glaucoma patients do not adhere to their medication regimens because they fail to internalize
the (health) costs of non-adherence, which may not occur until years or decades later. Behavioural economic
theory suggests that adherence rates can be improved by offering patients a near-term benefit. Our proposed
strategy is to offer adherence-contingent rebates on medication and check-up costs. This form of value pricing (VP)
ensures that rebates are granted only to those most likely to benefit. Moreover, by leveraging loss aversion, rebates
are expected to generate a stronger behavioural response than equivalent financial rewards.
Methods/Design: The main objective of the Study on Incentives for Glaucoma Medication Adherence (SIGMA) is to
test the VP approach relative to usual care (UC) in improving medication adherence. SIGMA is a randomized, controlled,
open-label, single-centre superiority trial with two parallel arms. A total of 100 non-adherent (Morisky Medication
Adherence Scale ≤6) glaucoma patients from the Singapore National Eye Centre are block-randomized (blocking factor:
single versus multiple medications users) into the VP and UC arms in a 1:1 ratio. The treatment received by VP patients
will be strictly identical to that received by UC patients, with the only exception being that VP patients can earn either
a 50 % or 25 % rebate on their glaucoma-related healthcare costs conditional on being adherent on at least 90 % or
75 % of days as measured by a medication event monitoring system. Masking the arm allocation will be precluded by
the behavioural nature of the intervention but blocking size will not be disclosed to protect concealment. The primary
outcome is the mean change from baseline in percentage of adherent days at month 6. A day will be counted as
adherent when the patients take all their medication(s) within the appropriate dosing windows.
Discussion: This trial will provide evidence on whether adherence-contingent rebates can improve medication
adherence among non-adherent glaucoma patients, and more generally whether this approach represents a promising
strategy to cost-effectively improve chronic disease management.
Trial registration: NCT02271269. Registered on 19 October 2014.
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Glaucoma refers to a group of eye conditions that lead
to damage to the optic nerve, which carries information
from the eye to the brain. If uncontrolled, glaucoma
first causes peripheral vision loss and eventually can
lead to blindness. Glaucoma affects approximately 60
million people worldwide and is one of the leading
causes of irreversible blindness [1]. In Singapore, glau-
coma, affects roughly 3 % of those over age 40 and the
total number of cases is growing due to Singapore’s
ageing population [2, 3]. The most important modifi-
able factors of visual field loss in glaucoma are peak intra-
ocular pressure (IOP), average IOP and fluctuations in
IOP [4–7]. The majority of patients with glaucoma or sus-
pected glaucoma are initially managed by IOP-reducing
single or multi-drug treatments consisting of topical
eye drops. This could be followed by surgical treatment
for those whose IOP is not adequately controlled via
medications [8, 9].
Correct use of medicated eye drops reduces IOP,
subsequently slowing visual field loss for nearly 90 % of
patients [10–13]. Despite the effectiveness of topical
medication in controlling disease progression, roughly
two-thirds of patients report some level of medication
non-adherence to their medication [14–16]. Interven-
tions to enhance medication adherence often focus on
one or a combination of four strategies: simplification,
education, social support and behaviour modification
[17]. Most simplification interventions focus on reducing
the number of doses per day, perhaps through extended-
release capsules, or the number of medications [17].
Simplifying dosage requirements has consistently been
shown to improve adherence [17–19]. However, there
is evidence of non-adherence amongst glaucoma patients
taking only one topical medication [20]. Education and
social support interventions aim to increase adherence
through greater knowledge transfer and increased self-
efficacy. Education and social support interventions have
shown some evidence of effectiveness in the short term,
but results are less compelling in the long term [21, 22].
Behavioural interventions cover a wide range of strategies,
such as pill organizers, reminder systems, and tailored
regimens [17]. These studies too have shown mixed re-
sults, with both positive and negative results relating to
the effectiveness of reminders, and no agreement on
which behavioural intervention works best [23–26]. In a
review of randomized control trials that seek to improve
medication adherence, those that were most effective were
multi-faceted, and included combinations of convenience,
education, reminders, and reinforcement [19]. However,
even the most effective interventions reviewed did not
lead to large improvements in adherence. As a result,
other strategies are needed.
Behavioural economics theory suggests that an im-
portant factor of non-adherence is that patients do not
perceive a clear cause-and-effect relationship between
non-adherence and the increased likelihood of disease
progression, which may not occur until well into the
future [27, 28]. As a result, many patients do not
internalize the consequences of non-adherence until it
is too late. One strategy to rectify this problem is to
provide a short-term reward for increased adherence.
Giuffrida et al. [29] reviewed 11 randomized incentive
trials conducted in the United States where patients
were paid either cash, gifts or vouchers for meeting
adherence targets to various treatments and health
services. These rewards, which ranged in value from
USD5 to nearly USD1000, showed improve adherence
in 10 out of the 11 studies reviewed. However, none
focused on glaucoma patients and results varied widely
across studies, suggesting that more research is needed
to identify an optimal strategy to cost-effectively improve
medication adherence [30].
In this trial we test a novel approach to improve medica-
tion adherence among glaucoma patients. The approach
consists of adherence-contingent rebates on medication
and check-up costs that are granted only when adherence
goals are met as verified by a medication event monitoring
system. Given that prescription refills and follow-up clinic
visits occur regularly, the rebates provide a tangible and
near-term benefit resulting from medication adherence.
This strategy, which has been suggested by Loewenstein
and colleagues [31], can be seen as a novel form of
value pricing (VP) in the context of value-based insur-
ance designs [32]. With standard value-based insurance
designs, the co-payment for clinically effective treat-
ments is reduced in efforts to increase their utilization.
With our intervention design, incentives are allocated
to medications that have not only been shown to be
clinically effective, but that are also being effectively
used by the patient, which represents a better use of re-
sources. Another important feature of our approach is
that incentives are provided in the form of rebates on
costs already incurred by the patient. By offering a
rebate that avoids a loss, as opposed to an equally sized
reward, loss aversion theory predicts that this approach
is likely to have a greater behavioural response [33].
This trial will provide evidence on whether adherence-
contingent rebates can improve medication adherence
among non-adherent glaucoma patients. Secondary ob-
jectives are to determine whether IOP and quality of
life can also be improved, and whether the interven-
tion represents a promising strategy to cost-effectively
improve glaucoma management. Finally, explanatory
analysis will aim at uncovering factors that might
moderate the intervention effect and explain medica-
tion adherence.
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Objectives
Primary objective: determine whether complementing
usual care (UC) with adherence-contingent rebates
according to a VP strategy is superior to UC alone in
improving medication adherence between baseline and
month 6.
Secondary objective 1: determine whether the IOP of
patients in the VP arm improves more (or deteriorates
less) than that of patients in the UC arm between baseline
and month 6.
Secondary objective 2: determine whether the glaucoma-
related (GQL-15) and generic health-related (EQ5D-5 L)
quality of life of patients in the VP arm improves more
(or deteriorates less) than that of patients in the UC
arm between baseline and month 6.
Secondary objective 3: determine whether the incremen-
tal cost-effectiveness ratio (ICER) of VP compared to UC
will be favourable relative to international benchmarks for
cost-effectiveness.
Explanatory analyses
(i) compare adherence levels and intervention effect
according to different definitions (aspects) of
medication adherence
(ii)determine factors that might moderate the intervention
effect on medication adherence and quality of life




The Study on Incentives for Glaucoma Medications
Adherence (SIGMA) trial is designed as a randomized,
controlled, open-label, single-centre superiority trial
with two parallel arms. A total of 100 non-adherent
glaucoma patients will be block-randomized (blocking
factor: single versus multiple medication users) into the
UC and VP arms in a 1:1 ratio. Baseline assessment
lasts 1 month, followed by a 5-month intervention. The
primary outcome is medication adherence as recorded
by an electronic medication container.
Study setting and eligibility criteria
All patients will be recruited at the Singapore National
Eye Centre (SNEC). Singapore is an island city-state
that has a population of 5.5 million and which is one of
the most densely populated countries in the world.
Singapore is a multicultural country consisting of Chinese
(76.2 %), Malay (15 %), Indian (7.4 %) and other (1.4 %)
ethnicities. The most widely spoken languages in Singapore
are English, Mandarin, Malay and Tamil. The vast majority
of those who speak Malay and Tamil are also fluent in
English.
SNEC is part of SingHealth, which is Singapore’s
largest public healthcare group. Since 1990, SNEC has
been providing a full range of high-quality eye care and
is a referral centre for complex cases both nationally and
internationally. With its research arm, the Singapore Eye
Research Institute (SERI), SNEC also extensively engages
in academic research. SNEC treats both high-income pa-
tients and low-income patients. All Singaporean citizens
and permanent residents are entitled to government
subsidies in case of referral, while low-income patients
can benefit from additional subsidies through various
government schemes. The study will be conducted in col-
laboration with Duke-NUS, which is part of the academic
medical centre SNEC belongs to.
Inclusion criteria
 Glaucoma patient taking at least one eye drop
medication
 Low medication adherence based on the 8-Item
Morisky Medication Adherence Scale (MMAS)
[34–36]
 Aged between 21 and 85 years
 Singaporean citizens or permanent residents
 Conversant in English or Mandarin
Exclusion criteria
 Stage 4 (severe) or Stage 5 (end-stage) glaucoma
according to the Glaucoma Staging System (GSS)
based on the Humphrey Visual Field [37].
 Patients who are not independently instilling their
medications all or most of the time.
Study arms
In this study, patients learn about their arm allocation
by phone 1 month after their enrolment. This is to col-
lect 1 month of baseline data on medication adherence.
The patients then remain in their respective study arm
for a duration of 5 months. In both arms, a question-
naire and clinical assessment will take place at baseline
and month 6.
During the baseline visit, the research optometrist
takes note of the glaucoma medication dosing schedule
(see Fig. 1) in the participant instruction booklet (see
Additional file 1) to ensure a uniform presentation of
adherence goals across participants. Medication adherence
will be monitored during the whole 6-month period by
means of electronic containers eCAPs™ (Information
Mediary Corporation, Ottawa, ON, Canada). An eCAP™ is
a medication event monitoring system with an inbuilt
electronic tag which records the time whenever it is
opened and closed. Each eye drop will be stored in separ-
ate vials with separate eCAPs™. At month 3, eCAPs™ are
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collected by a courier service, medication adherence is
calculated for months 2 and 3 and the eCAPs™ are returned
to the patients along with a short adherence report for that
period (see Additional files 2 and 3). The next assessment
period for medication adherence runs from months 4 to 6,
and adherence calculation takes place after the patients
returned their eCAPs™ at the month 6 study assessment.
Patients also receive a call at the end of months 2 and 5
to verify that they understand their arm allocation and
adherence goals, and that patients with multiple eye
drops keep their medication in the assigned eCAP™.
Arm 1: usual care (UC)
Patients attend routine check-ups with an ophthalmologist
where they have glaucoma eye drops prescribed for
them, which they then purchase at the SNEC pharmacy.
The frequency of check-ups varies between patients
depending on the severity of their condition. The deci-
sion is made by the ophthalmologist on how regularly
patients should return for check-ups, ranging from
3 months to once a year. IOP and visual acuity are
measured at every visit while visual field readings are
taken annually. Non-adherent patients may also be offered
glaucoma counselling if necessary. During a counselling
session, a nurse delivers an educational component on
effective glaucoma treatment. Counselling includes the
following components: (i) understanding of glaucoma and
visual field process with a focus on risk factors and symp-
toms, (ii) management and treatment of glaucoma, (iii)
medications usage with practical advice on self-application
of eye drops. In addition, the nurse counsellor determines
a dosing schedule for each medication that accommodates
the patient’s lifestyle and takes into account working
hours. During this discussion, the nurse counsellor under-
lines the health risks raised by non-adherence to the medi-
cation regimen.
In order to properly identify the effect of value pricing,
we brought the following deviations to usual care. First,
a short adherence report will be sent to the participants
as described above. Second, a non-contingent payment
of SGD30 will be made to them at months 3 and 6.
However, unlike VP patients, no financial incentive will
be given when they are adherent to their medications.
Arm 2: value pricing (VP)
The treatment received by VP patients is strictly identi-
cal to that received by UC patients, with the only excep-
tion being that VP patients can earn rebates on their
glaucoma-related healthcare costs contingent on being
sufficiently adherent to their medications.
Adherence is measured as the percentage of days
where the patients take all their medication(s) within the
appropriate dosing windows for the day. According to
this definition, if a patient fails to take a single dose dur-
ing the corresponding window, the whole day is counted
as non-adherent. This concept of adherent-day stresses
the importance of complying to the medication regimen
as a whole and to its schedule in efforts to limit detri-
mental IOP fluctuations.
Patients who achieve more than 90 % adherent days will
receive a rebate amounting to 50 % of their glaucoma-
related healthcare costs, and patients achieving between
75 % and 90 % of adherent days will receive a 25 % rebate.
Glaucoma-related healthcare costs comprise the out-of-
pocket healthcare expenditure of one clinic visit at SNEC
and 3 months’ worth of glaucoma medications per as-
sessment period. When calculating glaucoma-related
healthcare costs, a lower limit of SGD36.50 (the price
of a subsidized doctor visit at SNEC) and an upper
limit of SGD240 will be applied for those patients who
spend less or exceed these limits. This means that those
who qualify for a 50 % rebate will receive a rebate
amount comprised between SGD18.25 and SGD120 per
assessment period. Note that the rebate amounts will
be explained to the patient and written down in the
participant instruction booklet by the research optom-
etrist during the baseline visit. However, emphasis will
be given to the rebate rate (i.e., 25 % or 50 %) in order
Fig. 1 Glaucoma medication dosing schedule. Note: Window length is set at a minimum of 6 hours and a maximum of 8 hours in the morning,
afternoon or evening
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to be consistent with a value-based insurance design.
Rebate payment is made via ebanking but the amount
earned is added on the medication adherence report in
order to make it fully visible to the patient.
Outcome measures
Primary outcome
Our primary outcome is the mean change from baseline
in percentage of adherent days at month 6. A day will be
counted as adherent when the patients take all their
medication(s) within the appropriate dosing windows for
the day. The percentage of adherent days during month 1
(baseline) and month 6 will be calculated for each patient
and the difference in mean change between study arms
will be tested. The primary outcome is directly incentiv-
ized in the VP arm and not incentivized in the UC arm.
As a result, this outcome will appropriately capture the
behavioural change induced by value pricing, if any.
Secondary outcomes
– Monthly mean change from baseline in percentage of
adherent days at months 2 to 5 in order to monitor
adherence trajectories before the study end point
(month 6).
– Monthly change from baseline in the proportion of
patients with percentage of adherent days greater or
equal to respectively 75 % and 90 % over the study
period (i.e. from month 2 to 6). These outcomes are
of interest as they are defined according to the
adherence thresholds that VP patients need to meet
in order to receive their financial incentives.
– Mean change from baseline in IOP at month 6.
– Mean change from baseline in GQL-15 [38] score at
month 6 as a glaucoma-specific measure of quality
of life.
– Mean change from baseline in EQ-5D-5L [39] score
at month 6 as a generic measure of quality of life.
– Mean cost of financial incentives at month 6 in
the VP arm. Individual cost of financial incentives
will be calculated using the participants’ monthly
glaucoma-related healthcare costs recorded at
baseline and percentage of adherent days at
month 6 (i.e. primary outcome).
Explanatory outcomes
– Monthly mean change from baseline in percentage of
days where all doses where taken irrespective of time
at months 2 to 6.
– Monthly mean change from baseline in percentage
of doses taken within the appropriate dosing
windows at months 2 to 6.
– Monthly mean change from baseline in percentage
of doses taken irrespective of time at months 2 to 6.
– Mean change from baseline in the 8-Item Morisky
Medication Adherence Score [34–36] (MMAS) at
month 6 as this score is used to identify patients
with low adherence as part of the screening
process. The MMAS scale has been validated by
showing that it is a good predictor of anti-hypertensive
pharmacy refill adherence [34] and blood pressure
(BP) control [36]. The MMAS scale has been used
to measure adherence in a wide variety of chronic
conditions including glaucoma [40].
– Brief Illness Perception Questionnaire [41] (BIPQ)
score at baseline.
– Specific subscale of the Beliefs about Medication
Questionnaire [42] (BMQ) score at baseline.
Sample size
We chose to power the study to detect differences of ten
percentage points in average monthly percentage of
adherent days at 6 months between the two study arms.
This effect size is sufficient to measure the effects re-
ported by a majority of financial incentive studies [30]
and is in line with a recent study that also used percent-
age adherence measured by electronic caps as primary
end point [43]. In order to detect such effect size, a total
of 100 participants is needed. This calculation assumes a
two-sided statistical test of difference in means with a
5 % significance level and a power of 80 %. In addition,
the standard deviation of the monthly percentage of
adherent days is assumed to be no greater than 16.3 %,
which is the maximum standard deviation in dose-rate
adherence reported by Robin and colleagues [44]. Finally,
attrition over the 6-month study is assumed to be no
greater than 20 %.
Randomization
A computerized random number generator (sealed
envelope™) was used by the study principal investigator
(PI) and coordinator at Duke-NUS to create an assign-
ment schedule to allocate eligible participants into one
of the two study arms in ratio of 1:1. Randomization
was stratified according to the number of glaucoma
medications prescribed to patients (one versus multiple
eye drops) given that medication adherence has been
shown to be highly correlated with this factor [44]. For
allocation concealment, the study PI and project coordin-
ator enclosed the assignments in sequentially numbered,
opaque, sealed randomization envelopes before handing
them to the research optometrist on site. Blocking size will
not be disclosed to the study site to protect concealment.
Note that the behavioural nature of the intervention pre-
cludes masking the arm allocation to both the study team
and patient. Arm allocation will be revealed at the end of
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the 1-month baseline measurement of medication ad-
herence (see Fig. 2).
Patient recruitment, retention, withdrawal, and
discontinuation
During routine clinic visits at SNEC, ophthalmologists
will identify patients with problems adhering to their
glaucoma eye drops and check that their GSS score does
not exceed 4. The ophthalmologists will then refer the
patients to a trained research optometrist to verify eligi-
bility, take informed consent, and proceed with enrol-
ment. Trained site research coordinators will also assist
with consent taking and administer study questionnaires
when required. Referral can also occur through nurse
counsellors at the SNEC Glaucoma Counselling Clinic
(GCC) where some non-adherent patients are referred
Fig. 2 SIGMA patient timeline
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to by their ophthalmologists. Recruitment is planned to
last a year. As an incentive to join the study, patients will
receive a SGD10 voucher upon successful enrolment.
Patient retention in the trial will be promoted by fi-
nancial incentives. Patients will receive SGD10 when
they join the study, they will also receive SGD20 for
returning their eCAP(s)™ at month 3, and SGD30 at the
end of the study for completing the month 6 assess-
ment and returning the eCAP(s)™. Patients will also be
engaged by means of a short adherence report they will
receive at month 3 and month 6. Patient burden will be
minimized by the use of a courier service to collect and
return the eCAP™ in lieu of a clinic visit for the month
3 medication adherence assessment. Lost devices or
broken devices will be replaced free of charge to enable
the patient to continue participating in the study.
Patients are free to withdraw from the study at any
time. When possible, the research optometrist will ad-
minister a short exit questionnaire to inquire about the
reasons of the withdrawal and collect the study devices
from the patient. Patients who withdraw will receive
SGD15 for returning their eCAP(s)™ and SGD15 if they
agree to complete a short exit questionnaire. In addition,
patients will be discontinued from the study when their
glaucoma condition deteriorates to the point of requiring
surgical intervention or when they develop significant
comorbid conditions that lead their ophthalmologists to
discontinue their topical medications or prevents applica-
tion of medications without assistance.
Data collection
In order to record medication adherence, each patient will
be issued with up to three eCAPs™ depending on the
number of glaucoma medications the patient is prescribed.
Each device will be labelled with a number, based on when
the study device is set up and will run in ascending nu-
merical order (the number will not relate to the patient’s
unique ID number). Each vial will be labelled with the
name of the patient and the medication. For patients with
multiple medications the research optometrist will explain
to the patient which eCAP™ number corresponds to which
medication. This will be written into the patient instruc-
tion booklet (see Additional file 1) for ease of reference for
patients. The research optometrist will explain to the pa-
tient how to use the eCAP™ and test that the device is
properly working before the patient leaves the clinic. The
patient instruction booklet also provides information on
eCAP™ use along with the contact information for the
study team at SNEC and Duke-NUS in case patients have
any questions about their device. Patients will also be
reminded to report any loss or malfunction of their de-
vices to minimize data loss. If the patients report any issue
with their devices, a replacement will be immediately ar-
ranged by courier service. In addition to receiving calls to
reveal randomization and arrange device collection and
delivery, the patients will receive three follow-up calls (see
patient timeline, Fig. 2). During all calls, proper use and
working condition of the devices will be checked. For
multiple medication users, it will also be verified that the
correct medication is stored in the correct vial. For further
quality assurance, a copy of the eye drop dosing schedule
and instructions on eCAP™ use will be sent along with the
eCAPs™ and brief medication adherence report after the
month 3 assessment.
IOP will be measured using Goldmann Applanation
Tonometry (GAT). At baseline, the ophthalmologist
will take the IOP at the point of referral. The research
optometrist will then record this measurement in the
baseline checklist. The same workflow will be followed
at month 6 unless it is not possible to make this assess-
ment coincide with the patient’s clinic visit. In such
event, the research optometrist will take down the IOP
that was taken closest to the month 6 visit from the
patient’s medical record.
Paper-based questionnaires will be used at baseline
and month 6. Both questionnaires include the GQL-15
and EQ-5D-5 L instruments. The baseline questionnaire
also records the BIPQ and BMQ instruments along with
patient socioeconomic characteristics. The month 6 ques-
tionnaire also includes the patient’s MMAS responses and
score. These questionnaires will be self-administered
unless the patient has difficulties in which case it will be
administered by the research optometrist.
In addition, the research optometrist will fill out paper-
based checklists at baseline and month 6. In addition to
the patient’s IOP, the baseline checklist will record the
patient’s medication regime extracted from medical re-
cords. The month 6 checklist will record the patient’s
understanding and self-reported compliance to the study.
The paper-based screener will also contain the self-
reported MMAS responses and score.
All study documents are available in English and
Mandarin to ensure the study is open to a wide range
of the patient population. The research optometrist will
check for completeness of all study documents and
questionnaires on site and the Duke-NUS study team
will double-check this at the data entry point and follow
up in the event of any missing data. In efforts to promote
compliance to the study requirements, all patients will re-
ceive a small monetary reward for providing key study
data, as previously described - SGD10 upon successful en-
rollment, SGD20 for returning the eCAP™ at month 3 and
SGD30 for completing the month 6 assessment and
returning the eCAP™.
Data management and monitoring
The study devices are received from patients at months
3 and 6. The project coordinator will scan each study
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device using the CertiScan™ desktop reader and the data
will be downloaded to the Med-ic™ software. From the
software the data will be exported to an Excel file where
the project coordinator will check the validity of the
data. She will notably check whether multiple medica-
tion users have kept their medication in the correct
study device and will remedy the situation whenever
possible. The project coordinator will then save the data
as a text file and a statistician will run the file through a
tailored Stata program that automates adherence calcu-
lation. For data that is collected via questionnaires and
checklists, the project coordinator will oversee data
entry at SNEC. Data will be keyed into separate Excel
files that will be merged using the participant IDs. The
data entry sheets have been designed to only accept
values that are within the correct range, and data will be
double-entered by two different study team members to
minimize errors.
During the trial all paper-based documents and used
study devices will be stored in locked cabinets at SNEC
and Duke-NUS. After study completion, all paper-based
documents will be stored in a secured room at Duke-NUS
in a digital format (scanned documents stored on CD-
ROM). All source documents will be retained until at least
6 months after the end of the study and then securely
destroyed. Digital records will be kept for at least 15 years
and securely destroyed upon the publication of all pertin-
ent research studies/reports.
Once the first 25, 50, and 75 participants have success-
fully completed their month 6 assessment, primary and
secondary outcomes will be computed in both study
groups by a trained statistician. Attrition and missing
data patterns will also be analysed. The purpose of these
interim analyses is to detect potential issues that might have
arisen during the data collection process before the end of
the trial and to report preliminary results to SingHealth
CIRB (Centralised Institutional Review Board) on an annual
basis. No stopping rules have been defined for this trial.
The research optometrist will ask patients and care-
givers about potential adverse events. If a patient has
been hospitalized the research optometrist will copy
and file the patient discharge summary if it is available.
Reporting of adverse events involves notifying the
SingHealth CIRB and submitting the serious adverse
event (SAE) Reporting Form within the stipulated time
frame. The notifying and reporting requirements depend
on the severity, nature and causality of the event and there
are specific procedures that must be followed [45].
No data monitoring committee will be utilized for
this trial as the intervention has no impact on the
standard of care received by SNEC glaucoma patients
and therefore does not involve more than minimal
risks. This trial is subject to study review visits of and/
or audits by the SingHealth Research Quality Assurance
unit, which is responsible for ensuring that all investigator-
initiated research processes are conducted suitably, ad-
equately, effectively, and efficiently across the SingHealth
cluster. These study review visits/audits may be conducted




Change from baseline in percentage of adherent days at
month 6 will be linearly regressed on the (i) study arm
(VP vs. UC), (ii) baseline percentage of adherent days,
(iii) change in number of daily doses taken in order to
correct for potential medication change or number of
eCAPs™ tracked, and (iv) other baseline characteristics
(age, language spoken, income, IOP, BIPQ and BMQ
scores) in order to increase statistical efficiency. The
linear model will be estimated via ordinary least
squares (OLS) and the hypothesis of equality between
the mean change in primary outcome between the
study arms will be tested by testing whether the binary
variable indicating the study arms equals zero using a t
test. All tests will be bilateral, performed at the 5 %
level of statistical significance, and carried out using the
statistical software Stata version 13.1 (StataCorp LP,
College Station, TX, USA).
The analysis will be performed according to an
intention-to-treat approach. If multiple medication users
have faulty devices, adherence will be calculated based on
functioning devices. Remaining missing adherence data
will be imputed using Markov chain Monte Carlo multiple
imputation including as predictors all factors mentioned
above. In addition, for sensitivity analysis, baseline adher-
ence will be carried forward for patients who withdraw
from the study as those VP patients who do not achieve
their goals might disproportionally withdraw from the
study.
Secondary analyses
The same analysis described above will be conducted
for the change from baseline in percentage of adherent
days from months 2 to 6 in order to analyse the trajec-
tory of adherence change induced by the intervention.
All months will be simultaneously analysed and stand-
ard errors will be adjusted for individual clustering.
Next, logistic regressions of indicator variables indicat-
ing whether the 75 % and 90 % adherence goals are
achieved will be estimated from months 2 to 6. Regres-
sors will include the study arm, a variable indicating
whether the adherence goal was achieved at baseline,
change in number of daily doses taken and the same
baseline characteristics as for the primary analysis.
Changes from baseline in IOP and GQL-15 and EQ5D-
5 L scores at month 6 will be linearly regressed on the
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study arm, their baseline values, and the same other
baseline characteristics as for the primary analysis. If
the intervention shows improvements (relative to the
control group) both in terms of GQL-15 and EQ5D-5 L
scores, we will conduct an economic analysis using util-
ities derived from the change in EQ5D-5 L score. The
costs will be obtained from the financial incentives paid
during the last month of the trial and from assumptions
on operational and administrative costs incurred if the
intervention were to be scaled up. The perspective of the
analysis will be that of a governmental agency subsidizing
healthcare costs.
Explanatory analyses
The same analysis as for the primary outcome will be
performed using the alternative measures of medication
adherence listed in the explanatory outcomes section.
Next, the models used in the primary and secondary
analyses will be extended by adding interaction terms
between potential intervention moderators (presence of
comorbidities, glaucoma- and non-glaucoma-related
medication regimen, potential incentive amount, BIPQ
and BMQ variables, and patient sociodemographic
characteristics) and the binary variable indicating study
arms. Last, medication adherence levels at baseline will
be linearly regressed on potential factors of medication
adherence (presence of comorbidities, glaucoma- and non-
glaucoma-related medication regimen, BIPQ and BMQ
variables, and patient sociodemographic characteristics).
Ethics and dissemination
This study has been approved by the SingHealth Centra-
lised Institutional Review Board A (Ref 2013/852/A)
which oversees ophthalmology research at SingHealth.
The principle investigator is responsible for informing
the CIRB of any amendments to the protocol or other
study-related documents, as per local requirement.
Written informed consent will be collected from each
participant prior to inclusion in the study. The consent
process will be carried out at SNEC. Interested and po-
tentially eligible patients will be referred for the study by
their ophthalmologist, and a trained research optom-
etrist will explain the study to the patient in either Eng-
lish or Mandarin. The participant information sheet
and consent form (see Additional files 4 and 5), and all
other study documents will be available in both English
and Mandarin. If the patient is illiterate, the research
optometrist will read (or have the patient’s caregiver
read) the participant information sheet and consent
form in the presence of an impartial witness. In case
the patient is not able to sign, the research optometrist
will accept a thumb print in lieu of a handwritten signa-
ture. However, as this study will only include patients who
are able to adhere to a medication regimen without
assistance, patients are expected to be able to give consent
to participate in the study on their own. Therefore, we did
not make any additional provision for illiterate partici-
pants. Instead, we took measures to make participation as
simple as possible for all patients. The research optom-
etrist will paste the medicine label on each eCAP™ and
place the eye drop(s) into the eCAP(s)™ for all participants
who buy their medications on the day of recruitment. Fur-
ther, eCAP™ use does not require literacy as participants
only need to correctly close the eCAP™ on the medica-
tion container. This will be demonstrated by the re-
search optometrist during the baseline visit and can be
later verified by the participants as the eCAP™ beeps
when correctly closed. In addition, the research coord-
inator will verify that all participants with multiple eye
drops keep their medications in the assigned eCAP™
during the months 2 and 5 follow-up calls. No provi-
sions have been made for informed consent to be taken
from a legally acceptable representative of the patient.
No provisions have been made to compensate partici-
pants for research-related injuries as the study does not
involve more than minimal risks. However, compensa-
tion may be considered on a case-by-case basis for un-
expected injuries due to non-negligent causes.
A unique participant ID will be assigned to all pa-
tients who are successfully enrolled on the study. All
study questionnaires and checklists will only refer to
the participants using this ID number so the data is de-
identified. The participant patient identity log will be
kept separate from all other data collected at SNEC.
The hard copy will be kept in a locked cupboard with
restricted access at SNEC. An electronic copy will be
stored in Excel format at SNEC and will be password
protected. All study materials will be kept in locked
files at SNEC and Duke-NUS. Only the investigators
and authorized personnel directly involved with the
study will have access to the data. All data files will be
password protected and stored on a secure server at
Duke-NUS.
Investigators will have unrestricted access to the
research data upon completion of the trial. Main trial
results will be published irrespective of the magnitude
and direction of the effects and their statistical significance.
Discussion
A key consideration in incentive studies is that partici-
pants fully understand their adherence goals and reward
schemes. It is in particular crucial that participants do not
confuse the non-contingent payment with financial incen-
tives as the former is given to control group participants
irrespective of medication adherence while the latter is
earned by intervention group participants if they reach
their adherence goals. In order to make sure that this
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distinction has been properly understood, study team
members will ask the participants during the follow-up
calls to briefly describe the financial rewards they can re-
ceive and will correct any misunderstanding. The distinc-
tion between control and intervention group payments
will be further emphasized in the adherence reports that
will be sent at month 3 where the payment rationale is
briefly re-explained. At the follow-up study visit, the un-
derstanding of the participants will be re-assessed in order
to assess the quality of the study.
Further, adherence goals have been kept as simple as
possible to maximize the chances that they are properly
understood by all participants. This is why we defined
adherent days, which are the days where all medica-
tions are taken during the appropriate time windows.
The understanding of the adherence goals essentially
boils down to the awareness of the medication sched-
ule. As the medication schedule is part of usual care,
no additional burden is added by the study. As some
patients might not be fully aware of their medication
schedule in practice, this is repeated in the patient leaflet
(see Additional file 1) which is distributed to all partici-
pants at the beginning of the study. Most importantly, re-
quiring that all doses are taken at the right time for a day
to be counted as adherent emphasizes the importance of
not only reducing average IOP but also to contain detri-
mental IOP variations.
The percentage of adherent days is then used both to
define adherence goals for the participants and to calcu-
late the primary outcome for the study. This reflects the
behavioural nature of the intervention. The 5-month
intervention is expected to be long enough to generate po-
tential sustainable changes in medication taking behaviour
and resulting IOP but is likely insufficient to detect mean-
ingful differences in disease progression.
Measurement of the primary outcome critically de-
pends on all patients keeping their medication(s) stored
in their tracking device(s). This study requirement will
be emphasized at recruitment and reiterated during the
follow-up calls. The possibility of gaming (i.e. opening
and closing the tracking device without effectively taking
the medication) has also been considered. While the
medication causes little side effects, some patients might
want to save on medication costs. In efforts to counter
and detect this potential behaviour, participants will be
asked to sign a participation oath [46] and their medica-
tion purchases will be monitored. During the baseline
visit, participants will be asked to keep all their medica-
tion bills and bring them to the month 6 visit. Based on
the bills and a discussion with the participant, the re-
search optometrist will assess whether the purchases
correspond to 6 months of medications. While these
measures are not fully fail proof, our strategy is to
maximize the chances of receiving unbiased feedback by
having this discussion take place after all study payments
have been made to the participant and by asking non-
threatening questions on medication purchasing habits
during the trial. We apply a similar strategy to verify ad-
herence to the monitoring devices with the research op-
tometrist asking nonthreatening questions on eCAP™
use at the end of the month 6 assessment once all pay-
ments have been made to the participant.
We were mindful of keeping the patient burden low
throughout the trial. This is why we prioritized record-
ing intervention outcomes (medication adherence, IOP,
quality of life. and costs), potential reasons for non-
adherence (BIPQ and BMP) and additional information
at month 6 aimed at verifying data integrity as described
above. Doing so, we left aside potentially interesting
questions relating to medication adherence such as in-
formation on the use of digital technology that can assist
patients to take their medications. We also did not track
use of non-glaucoma-related medications for partici-
pants with comorbidities. However, we will be able to
test whether those participants taking other medications
benefit differently from the intervention. To do so, we
will analyse the potential moderating effect of comorbid-
ities and other medication regimen on glaucoma-related
medication adherence and both glaucoma-related and
generic quality of life. Even though there is scarce evi-
dence on the long-term effect of continuous financial
incentives [47], two recent studies, one on antipsychotic
depot medication [48] and one on statins [49] showed
sustained effects at one year. Our 6-month study will
determine whether adherent-contingent rebates can be
effective at improving medication adherence among glau-
coma patients. If effective, a longer study (at least 2 years)
should be undertaken to assess health gains in terms of re-
duction in visual field loss and long-term sustainability of
medication adherence. Further, improvements in medica-
tion adherence tend to dissipate after discontinuation of
the financial incentives [30]. An exception is the above
study [49] that showed evidence of habit formation
where adherence levels remained higher than at base-
line 3 months after the incentives were discontinued.
On the other hand, no study reported decreases in
medication adherence below baseline levels. More
generally, there is no evidence in the literature that in-
centives can be counterproductive for health-related
behaviours [50].
The above discussion illustrates the challenges raised
by the assessment of the value pricing strategy we
propose. This trial will provide a rigorous assessment of
this intervention that includes both mitigation strategies
addressing the limitations of the design and indicators of
the overall quality of the study. This study is the first to
use financial incentives to increase medication adherence
among glaucoma patients. More importantly, this study
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also uses a new form of financial incentives—adherence-
contingent rebates—and it will be valuable to determine
how this new approach is able to generate behavioural
change. We will compare the effect of our intervention
to those of other interventions aiming at improving
medication adherence of glaucoma patients [51] and to
those of financial incentive studies conducted in other
disease areas [30].
Trial status
Recruitment to the SIGMA study began in November
2014 and is still ongoing. As of 26 January 2016, 93 pa-
tients have been enrolled in the study.
Additional files
Additional file 1: SIGMA Participant Instruction Booklet. This booklet is
given to all patients who join the study. The booklet contains study
information and study team contact details. Additional details are added
to reflect the individual patient’s dosing schedule, 3-month healthcare
costs and rebate amounts. (PDF 844 kb)
Additional file 2: Participant Medication Adherence Report A_month 3
(usual care arm). This report is sent to patients in the usual care arm after
month 3 to inform patients of their adherence and explain the non-
contingent payment. (PDF 205 kb)
Additional file 3: Participant Medication Adherence Report A_month 3
(value pricing arm). This report is sent to patients in the value pricing arm
after month 3 to inform patients of their adherence and explain the
rebate amount they have earned. (PDF 207 kb)
Additional file 4: Participant Information Sheet and Consent Form
(English). All English-speaking patients will complete this consent form
before joining the study. The patient signs two copies, one copy is kept
by SERI, and one copy is given to the patient. (PDF 298 kb)
Additional file 5: Participant Information Sheet and Consent Form
(Mandarin). All Mandarin-speaking patients will complete this consent
form before joining the study. The patient signs two copies, one copy is
kept by SERI, and one copy is given to the patient. (PDF 252 kb)
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